Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from August 17, 2025

Partial Published before the outcome was known, scored automatically when the window closed on November 15, 2025.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$103.17 Published $121.74 Target $102.69 Window close $109.50 Peak
$100.00 – $104.00Entry zone — fair-value band
$103.17Published — price the day we called it
$121.74Target — the price the thesis aimed for
$109.50Peak — highest point inside the window, not a realized return
$102.69Window close — end-of-window price, context only

What happened

Partial

Reached 34% of the predicted growth at its peak, without hitting the target.

Peak price
$109.50
peak on September 9, 2025 — not a realized return
Peak gain
+6.1%
peak, from the publication price
Window close
$102.69
end-of-window price, context only
Days to target
—
Window
August 17, 2025 – November 15, 2025

The thesis — published August 17, 2025

Predicted growth
+18%
over the measurement window
Target price
$121.74
the price the thesis aimed for
Entry zone
$100.00 – $104.00
the fair-value band we waited for
Price at publication
$103.17
published August 17, 2025
Confidence
65%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Boston Scientific looks set for a near-term recovery after a pullback. On Aug 16, Jefferies repeated its Buy rating with a $130 target following a strong Q2. Earnings per share have grown 18.4% per year over five years, showing steady progress. The FDA began monitoring some older defibrillator leads on Aug 15; this bears watching, but it appears manageable. A 3-month move back toward the recent average price seems reasonable.

Primary drivers

  • Price looks beaten down, and buyers are likely to step in around here soon.
  • A well-known bank reaffirmed a Buy rating and set a $130 price target.
  • Earnings per share have risen steadily for years, strengthening the case.
  • The FDA is monitoring older device parts; current view is risk looks limited.

How it played out

BSX: the target was not reached

Lyra published BSX at $103.17 on 2025-08-17, looking for 18% growth over a short-term window. The thesis pointed to a pullback that looked overdone, buyers returning near the $100 to $104 entry zone, a Buy rating with a $130 target, steady earnings per share growth of 18.4% per year over five years, and older device-part monitoring that looked limited at publication.

Inside the window, BSX peaked at $109.50 on 2025-09-09, a 6.1% gain. It stayed below the $121.74 target and never reached it. By 2025-11-15, it ended at $102.69. The thesis partially played out, but the target missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals